Amgen to appeal rejection of bid to block Novartis biosimilar drug

SAN FRANCISCO, March 25 (Reuters) - Amgen Inc will appeal the rejection of its bid to block the sale of Novartis AG's biosimilar form of Neupogen, Amgen's blockbuster drug used to prevent infections in cancer patients, according to a court filing on Wednesday.